Dapoxetine

From Drugs Prescribing Information
Jump to: navigation, search
Click on "►" to expand:
Click on "►" to expand:

Contents

[edit] BRAND NAMES

[edit] STRUCTURE

Dapoxetine.jpg

[edit] MECHANISM OF ACTION

Dapoxetine is a short-acting selective serotonin-reuptake inhibitor (SSRI). Its mechanism of action in premature ejaculation is presumed to be linked to the inhibition of neuronal reuptake of serotonin and the subsequent potentiation of the serotonin’s action at the post synaptic cleft.

Dapoxetine taken "on-demand" results in a significant increase in intravaginal ejaculatory latency time when compared with placebo.

[edit] INDICATIONS

Dapoxetine is indicated for the treatment of premature ejaculation in men 18 to 64 years of age, who have all of the following:

  • Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes; and
  • Marked personal distress or interpersonal difficulty as a consequence of PE; and
  • Poor control over ejaculation.

Premature ejaculation (PE) is a major issue in male sexual health. The global prevalence of PE is estimated to be between 20% and 40%, making it the most common sexual dysfunction in men.

[edit] DOSAGE

Adult men (18 to 64 years of age):

The recommended starting dose for all patients is 30 mg, taken as needed approximately 1 to 3 hours prior to sexual activity. If the effect of 30 mg is insufficient and the side effects are acceptable, the dose may be increased to the maximum recommended dose of 60 mg. The maximum recommended dosing frequency is one dose every 24 hours.

Dapoxetine may be taken with or without food and it is recommended that tablets be taken with at least one full glass of water.

[edit] CONTRAINDICATIONS

  • Known hypersensitivity to dapoxetine
  • Patients with significant pathological cardiac conditions (such as heart failure (NYHA class II-IV), conduction abnormalities (second- or third-degree AV block or sick sinus syndrome) not treated with a permanent pacemaker, significant ischemic heart disease or significant valvular disease.
  • Patients with significant pathological cardiac conditions (such as heart failure (NYHA class II-IV), conduction abnormalities (second- or third-degree AV block or sick sinus syndrome) not treated with a permanent pacemaker, significant ischemic heart disease or significant valvular disease.
  • Concomitant treatment with thioridazine, or within 14 days of discontinuing treatment with thioridazine. Similarly, thioridazine should not be administered within 7 days after Dapoxetine has been discontinued
  • Concomitant treatment with serotonin reuptake inhibitors [selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs)] or other medicinal/herbal products with serotonergic effects [e.g., L-tryptophan, triptans, tramadol, linezolid, lithium, St. John’s Wort (Hypericum perforatum)] or within 14 days of discontinuing treatment with these medicinal/herbal products. Similarly these medicinal/herbal products should not be administered within 7 days after Dapoxetine has been discontinued
  • Concomitant treatment with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazodone, nelfinavir, atazanavir, etc.
  • Patients with moderate and severe hepatic impairment.

[edit] WARNINGS AND PRECAUTIONS

[edit] INTERACTIONS

[edit] PREGNANCY AND LACTATION

[edit] SIDE EFFECTS

The most common adverse drug reactions (>5%) reported during clinical trials were headache, dizziness, nausea, diarrhoea, insomnia and fatigue. Orthostatic hypotension and syncope was reported also in clinical trials.

[edit] RELATED LINKS

[edit] BIBLIOGRAPHY

[edit] REFERENCES

Sexual dysfunction pharmacotherapies
PDE5 inhibitors Avanafil   Sildenafil   Tadalafil   Vardenafil
Prostaglandins (Erectile dysfunction) Alprostadil
Premature ejaculation Dapoxetine